Valion Bio
VBIO
6 hedge funds and large institutions have $31.7K invested in Valion Bio in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.07% more ownership
Funds ownership: 0% → 0.07% (+0.07%)
45% less funds holding
Funds holding: 11 → 6 (-5)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
67% less capital invested
Capital invested by funds: $96.3K → $31.7K (-$64.7K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$72.6K |
| 2 |
Citigroup
New York
|
+$3.03K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.14K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$296 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$74 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSWM
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
|
-$63.8K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$10.3K |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$3.62K |
| 4 |
Millennium Management
New York
|
-$3.2K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.09K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $28.9K | +$72.6K | +982 | New |
|
|
2
Citigroup
New York
| $1.22K | +$3.03K | +41 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $1.06K | +$2.14K | +29 | +414% |
|
|
4
Osaic Holdings
Scottsdale,
Arizona
| $251 | +$296 | +4 | +80% |
|
5
UBS Group
Zurich,
Switzerland
| $208 | -$739 | -10 | -59% |
|
|
6
Wells Fargo
San Francisco,
California
| $19 | +$74 | +1 | New |
|
|
SSWM
7
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
| – | -$63.8K | -353 | Closed |
|
|
TSS
8
Two Sigma Securities
New York
| – | -$10.3K | -57 | Closed |
|
|
BFM
9
Boothbay Fund Management
New York
| – | -$3.62K | -20 | Closed |
|
|
10
Millennium Management
New York
| – | -$3.2K | -18 | Closed |
|
|
CSS
11
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$3.03K | -17 | Closed |
|
|
12
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$3.09K | -17 | Closed |
|
|
HF
13
HRT Financial
New York
| – | -$2K | -16 | Closed |
|
|
OGC
14
One68 Global Capital
New York
| – | -$2.02K | -11 | Closed |
|
VBIO Hedge Fund Activity: Q3 2023 in Review
6 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q3 2023, worth a combined $31.7K — down 67% from $96.3K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of VBIO and 3 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $72.6K. The largest seller was Sheets Smith Wealth Management, exiting entirely with an estimated $63.8K sold.
- 6 institutional investors held Valion Bio (VBIO) as of Q3 2023, down from 11 in Q2 2023.
- Funds reported $31.7K of Valion Bio stock for Q3 2023, down 67% quarter-over-quarter.
- 3 funds opened new Valion Bio positions in Q3 2023 and 8 closed out, a net change of -5 holders.
- The largest Valion Bio buyer in Q3 2023 was Citadel Advisors, an estimated $72.6K added.
- The largest Valion Bio seller in Q3 2023 was Sheets Smith Wealth Management, an estimated $63.8K sold.
Based on aggregated 13F filings for Q3 2023.